FDA Clearance Tracker · K243886
ExpressCore Biopsy Device
Last checked: Nov 20, 2026Latest source record: Apr 29, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Apr 29, 2025
Substantially Equivalent
Time to decision
132 days
Received Dec 18, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K243886
- Device name
- ExpressCore Biopsy Device
- Applicant
- Inrad, Inc.
- Applicant location
- Kentwood, MI
- Received
- Dec 18, 2024
- Decided
- Apr 29, 2025
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device type
- Instrument, Biopsy (KNW)
- Device class
- Class II
- Regulation
- 21 CFR 876.1075
- Specialty
- GI, Urology & Nephrology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code KNW. The earliest in FDA's data is K760868, decided Nov 1, 1976.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K243886
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Inrad, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Trilogy Tissue Marker510(k)
K240429 · Decided Nov 7, 2024 · 268 days after receipt
Device type: Marker, Radiographic, Implantable (NEU) · General & Plastic Surgery
- EasyMark Tissue Marker510(k)
K183503 · Decided Oct 17, 2019 · 304 days after receipt
Device type: Marker, Radiographic, Implantable (NEU) · General & Plastic Surgery
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.